In the TIPO-1 Phase 2 trial, participants taking 0.5mg of tesofensine lost an average of 10.6% of their body weight in just 24 weeks. That's roughly double what older weight loss medications could achieve at the time.
🔑 At a Glance
- Tesofensine blocks reuptake of dopamine, serotonin, AND norepinephrine simultaneously
- Phase 2 TIPO-1 trial: 10.6% body weight loss at 0.5mg over 24 weeks
- Works through the central nervous system — completely different from GLP-1 agonists
- Originally developed for Parkinson's disease before pivoting to obesity research
- Notable side effects include elevated heart rate and blood pressure
- Available as a capsule; not an approved pharmaceutical product
- Stacks interestingly with GLP-1s in theory, but no head-to-head human trials exist
Tesofensine didn't start as a weight loss drug. It was being tested for Parkinson's disease when researchers noticed something unexpected: the subjects were losing significant body weight. That accidental discovery launched a second development arc aimed squarely at obesity. What emerged is one of the most talked-about compounds in the space today.
This article breaks down the mechanism, the trial data, the comparison with GLP-1 agonists like semaglutide and tirzepatide, and what you need to know about the capsule format currently available.
What Is Tesofensine?
Tesofensine (also called NS2330) is a triple monoamine reuptake inhibitor originally developed by Danish pharma company NeuroSearch. It blocks the reuptake of three neurotransmitters at once: dopamine, serotonin, and norepinephrine.
Most people know reuptake inhibition from antidepressants. SSRIs block serotonin reuptake. SNRIs block serotonin and norepinephrine. Tesofensine does all three simultaneously. That's what makes it pharmacologically distinct.
The origin story matters. NeuroSearch initially pushed tesofensine through Phase 2 trials for Parkinson's and Alzheimer's. It didn't perform well enough for those indications. But the incidental weight loss data caught the attention of the obesity community. NeuroSearch pivoted, and the TIPO-1 trial was born.
How Tesofensine Works for Weight Loss
The weight loss effect comes from multiple overlapping mechanisms. They don't just add up — they compound.
Appetite suppression via CNS pathways. Elevated dopamine and norepinephrine in the brain's reward and hypothalamic circuits reduce hunger signaling. This is similar to how phentermine works, but the mechanism is reuptake inhibition rather than forced monoamine release. The result tends to be more sustained and less prone to the crash associated with amphetamine-type releasing agents.
Enhanced satiety from serotonin. The serotonin component adds early satiety signaling — you feel full faster during meals. SSRIs are not weight loss drugs on their own, but serotonin does play a role in meal termination. When combined with the dopamine/norepinephrine effect, the appetite suppression is significantly amplified.
Increased energy expenditure. Norepinephrine drives thermogenic effects through beta-adrenergic receptors. This raises resting metabolic rate modestly. It's part of why tesofensine works better than the pure appetite suppression numbers would predict.
Reduced food reward signaling. Dopamine reuptake inhibition blunts the hedonic drive to eat — the desire to eat for pleasure rather than hunger. This is a psychologically significant mechanism. Many obese individuals eat primarily in response to reward cues, not caloric need. Blunting that drive makes calorie restriction feel less effortful.
Dopamine + norepinephrine pathways reduce hunger signals at the hypothalamus level
Serotonin component enhances meal termination signals
Norepinephrine raises resting energy expenditure through beta-adrenergic activation
Reduces hedonic eating by dampening food reward signaling in dopamine circuits
Tesofensine Clinical Trial Results for Obesity
The TIPO-1 trial is the key dataset. Published in The Lancet in 2008, this was a double-blind, randomized, placebo-controlled trial involving 203 participants with obesity (BMI 30-40 kg/m²). Duration: 24 weeks.
Three doses were tested: 0.25mg, 0.5mg, and 1.0mg daily. All outperformed placebo significantly.
| Dose | Avg Weight Loss | % Body Weight | Completers Rate |
|---|---|---|---|
| Placebo | ~2.0 kg | ~2% | High |
| 0.25mg | ~6.7 kg | ~6.7% | Good |
| 0.5mg | ~11.3 kg | ~10.6% | Good |
| 1.0mg | ~12.8 kg | ~12.8% | Lower (side effects) |
The 0.5mg dose is the sweet spot. It produced substantial weight loss — 10.6% of baseline body weight — with a more manageable side effect profile than the 1.0mg arm. The 1.0mg group lost slightly more weight but had meaningfully higher dropout rates due to cardiovascular and CNS side effects.
For context, drugs like orlistat typically achieve 3-5% weight loss over a similar timeframe. Sibutramine (now withdrawn) achieved around 5-7%. Tesofensine at 0.5mg outperformed both.
Tesofensine for Obesity: Who Is It For?
Based on TIPO-1 inclusion criteria, the trial enrolled adults with a BMI of 30-40 kg/m². The compound showed the most consistent results in individuals with simple obesity rather than metabolic syndrome-driven weight gain, though secondary metabolic markers (fasting glucose, lipids) also improved alongside weight loss.
Who stands to benefit most?
Individuals where appetite dysregulation and hedonic eating are primary drivers of excess weight. People who struggle with cravings and food reward rather than just caloric intake tend to be the best candidates for CNS-targeting weight loss approaches. Tesofensine targets this population more directly than GLP-1 agonists do.
Those who haven't responded well to lifestyle interventions alone. Diet and exercise are the foundation, but the physiological reality is that obesity involves neurobiological adaptations that make sustained caloric restriction difficult without pharmacological support. Tesofensine addresses some of those neurobiological barriers directly.
Researchers studying CNS-mediated weight loss mechanisms. The compound is widely used in the space to understand the role of monoamine systems in energy regulation and obesity.
Tesofensine vs Semaglutide: A Direct Comparison
This is the comparison people actually want. Semaglutide (the active ingredient in Wegovy and Ozempic) has become the dominant weight loss drug of the current era, with trial data showing 15-17% weight loss at 2.4mg weekly doses. How does tesofensine stack up?
The honest answer: semaglutide wins on efficacy. Tesofensine at 0.5mg achieves roughly 10.6% weight loss vs. 15-17% for semaglutide at full therapeutic doses. But the mechanisms are completely different, and the comparison is more nuanced than raw percentages suggest.
| Compound | Mechanism | Avg Weight Loss | Main Side Effects | Availability | Form |
|---|---|---|---|---|---|
| Tesofensine | Triple monoamine reuptake inhibitor | ~10.6% (0.5mg, 24 wks) | Elevated HR, blood pressure, insomnia, anxiety | Compound | Oral capsule |
| Semaglutide | GLP-1 receptor agonist | ~15-17% (2.4mg, 68 wks) | Nausea, vomiting, GI distress, pancreatitis risk | Prescription (Wegovy) / compounded semaglutide | Weekly injection / oral (Rybelsus) |
| Tirzepatide | GLP-1 + GIP dual agonist | ~20-22% (15mg, 72 wks) | Nausea, GI issues, injection site reactions | Prescription (Zepbound) / tirzepatide for weight loss | Weekly injection |
Key differences worth noting:
Timeline. Tesofensine's 10.6% was achieved in 24 weeks. Semaglutide's headline numbers come from 68-week trials. The comparison is not apples-to-apples. Some researchers believe tesofensine's short-term efficacy rate is actually competitive when normalized to trial duration.
Mechanism independence. Because tesofensine works through completely different pathways than GLP-1 agonists, there's theoretical interest in combination approaches. The two classes don't overlap in mechanism, which means they could potentially address different obesity drivers simultaneously. This is an area of active research interest, not established clinical practice.
Side effect profiles are different. GLP-1 agonists cause GI distress — nausea, vomiting, and digestive slowing are common. Tesofensine causes stimulant-type effects — elevated heart rate, blood pressure, potential anxiety and insomnia. Neither is trivial. The side effect profile of tesofensine is more concerning for cardiovascular safety in certain populations.
Oral vs. injectable. Tesofensine is taken orally as a capsule. This is a practical advantage for subjects who prefer not to inject weekly. The convenience factor is real.
Tesofensine vs Tirzepatide and Other GLP-1s
Tirzepatide is the current efficacy leader. At 15mg weekly doses over 72 weeks, the SURMOUNT-1 trial showed average weight loss of around 20-22%. That's roughly double what tesofensine achieves. If maximum weight loss efficacy is the primary goal, tirzepatide is the frontrunner among available compounds.
But tirzepatide is an injectable, requires dose titration over several weeks, and carries GI side effects that some subjects find severe. For people studying CNS-mediated obesity mechanisms specifically, tesofensine provides data that GLP-1 agonists simply cannot.
Peptides for weight loss cover a wide spectrum of mechanisms. Tesofensine is unique in targeting the monoamine system so aggressively. Emerging compounds like retatrutide combine GLP-1, GIP, and glucagon receptor agonism — a triple hormone approach that may eventually outperform both tesofensine and tirzepatide in terms of total weight reduction.
The landscape is evolving fast. Tesofensine remains relevant not because it's the strongest single agent, but because its mechanism fills a distinct niche that GLP-1 agonists don't cover.
Tesofensine Capsules: The Research Format
Tesofensine is available in capsule form from vendors. This is the format used by most researchers working with the compound today.
Typical capsule concentrations available: 500mcg (0.5mg) per capsule. This aligns with the primary dose from TIPO-1 showing the best efficacy-to-tolerability ratio.
Standard protocols reference once-daily oral dosing. The compound has a long half-life (approximately 220 hours), which means it accumulates to steady state over several weeks of dosing. Researchers should account for this buildup period when designing protocols — effects and side effects tend to intensify over the first 2-4 weeks as plasma concentrations rise.
Capsule format makes administration straightforward and eliminates the cold chain storage requirements and injection preparation needed for injectable peptides. For research settings where injection protocols are inconvenient, tesofensine capsules offer a practical alternative.
Side Effects and Safety Considerations
Tesofensine has a real side effect profile. Minimizing this would be inaccurate. The cardiovascular effects in particular require attention.
Heart rate elevation. The TIPO-1 trial showed average heart rate increases of 7-8 beats per minute in the 0.5mg group. At 1.0mg, this was higher. For healthy individuals with normal baseline cardiovascular function, this is generally tolerable. For anyone with pre-existing cardiac conditions, this is a significant concern.
Blood pressure. Systolic blood pressure increases were modest in the 0.5mg group but more pronounced at 1.0mg. Monitoring blood pressure during protocols is standard practice.
Insomnia and sleep disruption. The norepinephrine and dopamine components produce stimulant-like effects that can disrupt sleep. Dosing earlier in the day rather than evenings is the conventional approach to mitigate this.
Anxiety and restlessness. Some subjects experience mild anxiety, particularly during the accumulation phase as plasma concentrations build toward steady state. This typically stabilizes.
Dry mouth and constipation. Common stimulant-associated side effects seen in a portion of TIPO-1 participants. Generally mild.
Appetite suppression may be excessive at higher doses. At 1.0mg, some participants experienced appetite suppression so pronounced it interfered with adequate nutrition intake. This is not a theoretical concern.
Where to Get Tesofensine Capsules
Tesofensine capsules are available from Limitless Life Nootropics, one of the vendors that carries this compound consistently.
Limitless offers tesofensine in capsule form at concentrations consistent with TIPO-1 dosing parameters. They're one of the more established suppliers in this space for CNS-targeted compounds.
When sourcing any compound, third-party testing and supplier reputation matter. Look for certificate of analysis documentation and established track records. Tesofensine is not a widely available compound, so supply consistency is worth factoring into supplier selection.